Overall, these results suggest that both NASH and anti-IL-1β monoclonal treatment promotes hepatocellular proliferation, epithelial-mesenchymal transition and contributes to the development to a microenvironment that enables immune evasion. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatohepatitis.